Nanopharm and Fluidda are collaborating on a computational approach for assessing bioequivalence in inhaled generics. Their project aims to ease the USFDA approvals process for a drug class whose pharmacokinetic properties are notoriously difficult to observe.
Nanopharm has embarked on an exclusive collaboration with respiratory imaging company Fluidda to develop computational methods for assessing bioequivalence in orally inhaled and nasal drugs.
Their computational approach aims to expedite US Food and Drug Administration approval procedures for these products.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
